Cas:81586-97-2 (8R,9S,13S,14S)-1,4,16,16-tetradeuterio-2,3-dihydroxy-13-methyl-6,7,8,9,11,12,14,15-octahydrocyclopenta[a]phenanthren-17-one manufacturer & supplier

Chemical Name:(8R,9S,13S,14S)-1,4,16,16-tetradeuterio-2,3-dihydroxy-13-methyl-6,7,8,9,11,12,14,15-octahydrocyclopenta[a]phenanthren-17-one

CAS.NO:81586-97-2

Synonyms:2-Hydroxyestrone-d4;Catecholestrone-d4

Molecular Formula:C₁₈H₁₈D₄O₃

Molecular Weight:290.39000

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:57.53000

Exact Mass:290.18200

LogP:3.52300

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 2-Hydroxyestrone-d4 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Catecholestrone-d4 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-Hydroxyestrone-d4 Use and application,Catecholestrone-d4 technical grade,usp/ep/jp grade.

Related News: He said the FDA made its decision by fiat, and had not asked its advisors to consider whether the drug’s ability to remove a type of brain plaques known as beta amyloid would improve outcomes for patients. (8R,9S,13S,14S)-1,4,16,16-tetradeuterio-2,3-dihydroxy-13-methyl-6,7,8,9,11,12,14,15-octahydrocyclopenta[a]phenanthren-17-one manufacturer In addition, a high-standard GMP workshop is under construction and is expected to be put into production within the year. As the capacity bottleneck is broken, the pharmaceutical intermediate business is expected to grow rapidly in the future, providing the company with new growth momentum. (8R,9S,13S,14S)-1,4,16,16-tetradeuterio-2,3-dihydroxy-13-methyl-6,7,8,9,11,12,14,15-octahydrocyclopenta[a]phenanthren-17-one supplier A GSK spokesman said it was not yet clear by when ViiV would be able to address the FDA��s concerns. (8R,9S,13S,14S)-1,4,16,16-tetradeuterio-2,3-dihydroxy-13-methyl-6,7,8,9,11,12,14,15-octahydrocyclopenta[a]phenanthren-17-one vendor In the current trial, a total of 196 patients were randomly chosen to receive either the vaccine or a placebo. (8R,9S,13S,14S)-1,4,16,16-tetradeuterio-2,3-dihydroxy-13-methyl-6,7,8,9,11,12,14,15-octahydrocyclopenta[a]phenanthren-17-one factory In addition, a high-standard GMP workshop is under construction and is expected to be put into production within the year. As the capacity bottleneck is broken, the pharmaceutical intermediate business is expected to grow rapidly in the future, providing the company with new growth momentum.